Prophylactic antiviral therapy and all-cause mortality in cancer patients with hepatitis B e antigen-negative chronic hepatitis B virus infection receiving immunosuppressive therapy
Initiation of prophylactic antiviral therapy was associated with significant reductions in mortality and HBVr within 1 year in cancer patients with HBeAg-negative chronic HBV infection who received IST in real-world clinical practice.
Authors
- Yuxin Lin (ORCID: https://orcid.org/0000-0001-6543-0317)
- Sheng Nie (ORCID: https://orcid.org/0000-0002-8267-7909)
- Yanqin Li (ORCID: https://orcid.org/0000-0001-5107-1296)
- Xin Ping Xu (ORCID: https://orcid.org/0000-0002-6324-5211)
- Licong Su (ORCID: https://orcid.org/0000-0002-3085-909X)
- Fan Luo (ORCID: https://orcid.org/0000-0002-0216-1604)
- Shi-Yu Zhou (ORCID: https://orcid.org/0000-0002-8343-4810)
- Qi Gao (ORCID: https://orcid.org/0000-0002-7794-9869)
- Lisha Cao
- Ruixuan Chen (ORCID: https://orcid.org/0000-0002-2925-9484)
- Zhixin Guo
- Guobao Wang (ORCID: https://orcid.org/0000-0003-4050-3385)
Institutions
- Nanfang Hospital (CN)
- National Clinical Research (US)
- Southern Medical University (CN)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1093/jnci/djaf032
- Citations
- 2
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 2.64